Thymus Cancer Market is expected to register significant growth over the forecast period. The market was valued at approximately USD 481.85 Million in 2018 and is projected to register a 5.2% CAGR over the forecast period.
Thymus cancer occurs in a small organ that is located behind the sternum (breastbone) in front of the chest.
The rising prevalence of thymus cancer is expected to drive market growth. According to the National Cancer Institute (NCI), the incidence rate for thymoma is 0.15 cases per 100,000 people, as of 2016. Moreover, increasing research and development expenditure in the field of oncology for the development of innovative drugs to treat cancer is also expected to boost market growth.
However, the side effects of the treatment and stringent government regulations are expected to hamper the market growth.
Thymus Cancer Market Segmentation
The Global Thymus Cancer Market has been segmented into Cancer Type, Treatment Type, End User, and Region.
Based on cancer type, the global thymus cancer market has been segmented into thymoma and thymic carcinoma.
The global thymus cancer market, by treatment type, has been segmented into chemotherapy, surgery, radiation therapy, and others.
The global thymus cancer market, by end user, has been segmented into hospitals & clinics, research & academic institutes, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The thymus cancer market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European thymus cancer market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe.
The thymus cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The Middle East & Africa thymus cancer market has been segmented into the Middle East and Africa.
Thymus Cancer Market Key Players
Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), AstraZeneca (UK), Mylan NV (US), Johnson & Johnson Services, Inc. (US), Onxeo (France), Takeda Pharmaceutical Company Limited (Japan), Tiziana Life Sciences plc (UK), and Teva Pharmaceutical Industries Ltd (Israel) are some of the Key Players operating in the Global Thymus Cancer Market.
Global Thymus Cancer Market, by Cancer Type
Global Thymus Cancer Market, by Treatment Type
- Chemotherapy
- Surgery
- Radiation Therapy
- Others
Global Thymus Cancer Market, by End User
- Hospitals and Clinics
- Research and Academic Institutes
- Others
Request Customization
Get a Sample
Get a Sample
Request Customization